ATE495173T1 - Kinase-inhibitoren - Google Patents

Kinase-inhibitoren

Info

Publication number
ATE495173T1
ATE495173T1 AT09011369T AT09011369T ATE495173T1 AT E495173 T1 ATE495173 T1 AT E495173T1 AT 09011369 T AT09011369 T AT 09011369T AT 09011369 T AT09011369 T AT 09011369T AT E495173 T1 ATE495173 T1 AT E495173T1
Authority
AT
Austria
Prior art keywords
biohydrolysable
kinase inhibitors
solvate
arthritis
hydrate
Prior art date
Application number
AT09011369T
Other languages
English (en)
Inventor
Sanjib Das
Jason Brown
Qing Dong
Xianchang Gong
Stephen Kaldor
Yan Liu
Bheema PARASELLI
Nicholas Scorah
Jeffrey Stafford
Michael Wallace
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE495173T1 publication Critical patent/ATE495173T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT09011369T 2005-10-07 2006-10-10 Kinase-inhibitoren ATE495173T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72461905P 2005-10-07 2005-10-07

Publications (1)

Publication Number Publication Date
ATE495173T1 true ATE495173T1 (de) 2011-01-15

Family

ID=37622078

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09011369T ATE495173T1 (de) 2005-10-07 2006-10-10 Kinase-inhibitoren

Country Status (28)

Country Link
US (2) US8119655B2 (de)
EP (2) EP1931669A1 (de)
JP (1) JP5150878B2 (de)
KR (1) KR20080051153A (de)
CN (1) CN101356172B (de)
AT (1) ATE495173T1 (de)
AU (1) AU2006302135B2 (de)
BR (1) BRPI0616950A2 (de)
CA (1) CA2624610A1 (de)
CR (1) CR9886A (de)
CY (1) CY1111346T1 (de)
DE (1) DE602006019651D1 (de)
DK (1) DK2133349T3 (de)
EA (1) EA015902B1 (de)
ES (1) ES2358006T3 (de)
GE (1) GEP20125368B (de)
HR (1) HRP20110220T1 (de)
IL (1) IL190306A0 (de)
MA (1) MA29796B1 (de)
MY (1) MY146989A (de)
NO (1) NO20081564L (de)
NZ (1) NZ566866A (de)
PL (1) PL2133349T3 (de)
PT (1) PT2133349E (de)
RS (1) RS51897B (de)
SI (1) SI2133349T1 (de)
WO (1) WO2007044779A1 (de)
ZA (1) ZA200802820B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP5119154B2 (ja) 2005-09-22 2013-01-16 インサイト・コーポレイション Ｊａｎｕｓキナーゼの四環系阻害剤
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010500961A (ja) * 2006-08-02 2010-01-14 武田薬品工業株式会社 α−カルボリン誘導体およびその製造方法
EP2079696A2 (de) * 2006-10-09 2009-07-22 Takeda San Diego, Inc. Kinase-inhibitoren
GEP20135728B (en) * 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
EP2223925A1 (de) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase-Inhibitoren
EP2121692B1 (de) * 2006-12-22 2013-04-10 Incyte Corporation Substituierte heterozyklen als inhibitoren von janus-kinase
WO2009004329A1 (en) 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
KR20100129308A (ko) * 2008-02-28 2010-12-08 다케다 야쿠힌 고교 가부시키가이샤 약학 조성물
EP2283014A1 (de) * 2008-04-16 2011-02-16 Takeda Pharmaceutical Company Limited Polymorphe des hydrochloridsalzes von 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indol-7-carbonsäureamid und verfahren zu deren verwendung
US20110184178A1 (en) * 2008-04-16 2011-07-28 Takeda Pharmaceutical Company Limited Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
US20090312288A1 (en) * 2008-04-16 2009-12-17 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2324024B1 (de) 2008-06-11 2012-09-26 Genentech, Inc. Diazacarbazole und anwendungsverfahren
WO2009151598A1 (en) * 2008-06-11 2009-12-17 Genentech, Inc. Diazacarbazoles and methods of use
AR072084A1 (es) * 2008-06-12 2010-08-04 Sanofi Aventis Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica como inhibidores de las quinasas pim
DE102008052943A1 (de) 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
US8853391B2 (en) * 2008-12-18 2014-10-07 Merck Patent Gmbh Tricyclic azaindoles
FR2950891B1 (fr) * 2009-10-06 2012-11-09 Sanofi Aventis Derives d'azacarbolines 9h-pyrrolo[2,3-b:5,4-c']dipyridine, leur preparation et leur utilisation therapeutique
FR2943674B1 (fr) * 2009-03-24 2013-02-22 Sanofi Aventis Derives d'azacarbolines,leur preparation et leur utilisation therapeutique
CN102365282A (zh) * 2009-03-24 2012-02-29 赛诺菲 9H-吡咯并[2，3-b：5，4-c’]二吡啶氮杂咔啉衍生物、其制备方法及其治疗用途
FR2953838B1 (fr) * 2009-12-10 2012-02-24 Sanofi Aventis Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique
FR2953837B1 (fr) * 2009-12-10 2012-03-09 Sanofi Aventis Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique
US20110183938A1 (en) * 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
CN102372707B (zh) * 2010-08-16 2015-08-19 上海药明康德新药开发有限公司 6-甲基-4-溴-1,6-二氢吡咯[2,3-c]吡啶-7-酮的合成方法
US9040540B2 (en) 2011-11-09 2015-05-26 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
KR20210156333A (ko) 2012-05-15 2021-12-24 캔써 리서치 테크놀로지 리미티드 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
PL2810931T3 (pl) 2013-06-06 2018-09-28 Solvay Sa Sposób otrzymywania halogenowanych bezwodników kwasów karboksylowych
ES2770123T3 (es) 2015-02-02 2020-06-30 Forma Therapeutics Inc Acidos 3-alquil-4-amido-bicíclicos [4,5,0]hidroxámicos como inhibidores de HDAC
TW201636329A (zh) 2015-02-02 2016-10-16 佛瑪治療公司 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸
WO2016187767A1 (en) * 2015-05-25 2016-12-01 Hutchison Medipharma Limited Pharmaceutical compositions and use thereof
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
EP3472131B1 (de) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- und 6-hydroxamsäureindane als hdac-inhibitoren
TWI903299B (zh) 2018-03-08 2025-11-01 美商英塞特公司 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
ES2991427T3 (es) 2018-05-04 2024-12-03 Incyte Corp Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
ES3004565T3 (en) * 2018-08-14 2025-03-12 Ossifi Therapeutics Llc Pyrrolo - dipyridine compounds for the treatment of bone loss
CN113166058A (zh) 2018-08-14 2021-07-23 奥斯特克有限公司 氟β-咔啉化合物
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
US11773093B1 (en) 2023-01-19 2023-10-03 King Faisal University N-(pyrimido[2,3-b]indol-7-yl)acetamide compounds as antibacterial agents

Family Cites Families (302)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB828847A (en) 1956-12-14 1960-02-24 Ilford Ltd Improvements in or relating to cyanine dyes
FR1242962A (fr) 1959-08-25 1960-10-07 Kodak Pathe Nouveau procédé pour la préparation de colorants sensibilisateurs de la série des cyanines et des mérocyanines et produits obtenus
GB1268773A (en) 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
DE2844606A1 (de) 1978-10-13 1980-04-24 Bayer Ag Heterocyclische farbstoffe
US4260776A (en) 1978-01-25 1981-04-07 Bayer Aktiengesellschaft Heterocyclic dyestuffs
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
GB9222253D0 (en) 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
ATE212993T1 (de) * 1995-07-06 2002-02-15 Novartis Erfind Verwalt Gmbh Pyrolopyrimidine und verfahren zu ihrer herstellung
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US5962312A (en) 1995-12-18 1999-10-05 Sugen, Inc. Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US6093723A (en) * 1996-08-09 2000-07-25 Boehringer Ingelheim Pharmaceuticals, Inc. 4-substituted beta-carbolines and analogs thereof
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
WO1999009160A1 (en) 1997-08-15 1999-02-25 Chugai Seiyaku Kabushiki Kaisha Cell cycle-regulating proteins
ATE368665T1 (de) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6143480A (en) 1998-09-03 2000-11-07 Fuji Photo Film Co., Ltd. Leuco dye and image recording medium containing the same
US6706491B1 (en) 1999-04-09 2004-03-16 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by p21
US20050113460A1 (en) 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
AU6237700A (en) 1999-07-21 2001-02-13 University Of Massachusetts Kinase blocking polypeptides and uses thereof
WO2001014378A1 (en) 1999-08-23 2001-03-01 Shionogi & Co., Ltd. PYRROLOTRIAZINE DERIVATIVES HAVING sPLA2-INHIBITORY ACTIVITIES
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CZ20021010A3 (cs) 1999-09-21 2002-06-12 Astrazeneca Ab Nové sloučeniny chinazolinu a farmaceutické kompozice, které je obsahují
CN1391562A (zh) 1999-09-21 2003-01-15 阿斯特拉曾尼卡有限公司 用作药物的喹唑啉衍生物
GB9922173D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
WO2001047922A2 (en) 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles
JP2003520855A (ja) 2000-01-28 2003-07-08 アストラゼネカ アクチボラグ 化学的化合物
EP1200422A2 (de) 2000-02-05 2002-05-02 Vertex Pharmaceuticals Incorporated Pyrazole enthaltende zusammensetzungen und ihre verwendung als erk-inhibitoren
WO2001056993A2 (en) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
EP1134221A1 (de) 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituierte beta-Carboline als lkB-Kinasehemmer
KR100826817B1 (ko) * 2000-03-15 2008-05-02 사노피-아벤티스 도이칠란트 게엠베하 치환된 베타-카볼린
EP1209158A1 (de) 2000-11-18 2002-05-29 Aventis Pharma Deutschland GmbH Substitutierte beta-Carboline
JP2001294772A (ja) 2000-04-10 2001-10-23 Fuji Photo Film Co Ltd 着色組成物、インクジェット用インク及びインクジェット記録方法
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6555329B2 (en) 2000-06-09 2003-04-29 Boehringer Ingelheim International Gmbh Method for identifying compounds altering higher-order chromatin-dependent chromosome stability
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
EE200200715A (et) 2000-06-28 2004-08-16 Astrazeneca Ab Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
AU2002222933A1 (en) 2000-07-13 2002-01-30 Millennium Pharamaceuticals, Inc. Inhibitors of factor xa
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
KR100904157B1 (ko) 2000-08-10 2009-06-23 파마시아 이탈리아 에스.피.에이. 키나제 억제제로서 활성인 비사이클로-피라졸, 이의제조방법 및 이를 포함하는 약제학적 조성물
US6352858B1 (en) 2000-09-11 2002-03-05 Isis Pharmaceuticals, Inc. Antisense modulation of BTAK expression
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DK1318997T3 (da) 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20040019046A1 (en) 2000-11-27 2004-01-29 Paolo Pevarello Phenylacetamido-pyrazole derivatives and their use as antitumor agents
US6455559B1 (en) 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
CA2430065C (en) 2000-11-28 2008-05-20 Pfizer Products Inc. Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents
FR2818278B1 (fr) 2000-12-20 2003-02-28 Sod Conseils Rech Applic Inhibiteurs de kinases dependantes des cyclines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
WO2002050079A1 (fr) 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
US6864255B2 (en) 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
OA12599A (en) 2001-05-14 2006-06-08 Pfizer Prod Inc Tartrate salts of 5,8, 14-triazatetracyclo Ä10.3.1.o2,11.o4.9Ü-hexadeca2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof.
US20050090498A1 (en) 2001-05-24 2005-04-28 Kiyohiro Samizu 3-Quinolin-2(1h)-ylideneindolin-2-one derivative
WO2002096867A2 (en) 2001-05-30 2002-12-05 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
US6762179B2 (en) 2001-05-31 2004-07-13 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinase
JP4523271B2 (ja) 2001-06-01 2010-08-11 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール化合物
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
BR0210940B1 (pt) 2001-06-22 2014-12-23 The Procter & Gamble Company Composição para tratamento de artigos de tecido, composição detergente consumível e método para o preparao de uma composição para tratamento de artigos de tecido a partir de uma composição detergente consumível"
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
CZ2004107A3 (cs) 2001-07-19 2004-04-14 Pharmacia Italia S. P. A. Fenylacetamido-thiazolové deriváty, způsob jejich přípravy a jejich použití jako protinádorových farmaceutických prostředků
US20040235867A1 (en) 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
WO2003012046A2 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
WO2003011287A1 (en) 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Pyrazolon derivatives as inhibitors of gsk-3
CZ2004168A3 (cs) 2001-08-06 2004-05-12 Pharmaciaáitaliaás@P@A Aminoizoxazolové derivátyŹ účinné jako kinázové inhibitoryŹ způsob jejich přípravy a farmaceutické prostředkyŹ které je obsahují
US20030073692A1 (en) 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
US6927293B2 (en) 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
ES2286275T3 (es) 2001-09-19 2007-12-01 Pharmacia Corporation Compuestos de pirazolo sustituidos para el tratamiento de la inflamacion.
BR0212611A (pt) 2001-09-19 2004-08-17 Pharmacia Corp Compostos de pirazolila substituìdos para o tratamento da inflamação
MXPA04002070A (es) 2001-09-19 2004-06-07 Pharmacia Corp Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
JP2005507892A (ja) 2001-09-19 2005-03-24 ファルマシア・コーポレーション 炎症の治療のための置換されたピラゾリルベンゼンスルファミド化合物
ES2357502T3 (es) 2001-09-26 2011-04-27 Pfizer Italia S.R.L. Derivados de aminoindazol activos como inhibidores de quinasa, procedimiento para su preparación y composiciones farmaceuticas que los contienen.
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
EP1438053B1 (de) 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
US20040010027A1 (en) 2001-12-17 2004-01-15 Pharmacia & Upjohn Spa Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
ES2333702T3 (es) 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
ATE468336T1 (de) 2002-03-15 2010-06-15 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
ATE433973T1 (de) 2002-03-15 2009-07-15 Vertex Pharma Azolylaminoazine als inhibitoren von proteinkinasen
ES2289279T3 (es) 2002-03-15 2008-02-01 Vertex Pharmaceuticals Incorporated Composiciones utiles como inhibidores de proteinquinasas.
EP1485100B1 (de) 2002-03-15 2010-05-05 Vertex Pharmaceuticals Incorporated Azolylaminoazine als proteinkinasehemmer
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
EP1496906A4 (de) 2002-04-08 2006-05-03 Merck & Co Inc Hemmer der akt aktivität
AU2003244978A1 (en) 2002-04-15 2003-10-27 Inserm Methods to identify anti-tumoral agents inhibiting rasgap / aurora kinase interactions
US7304061B2 (en) 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
ATE457728T1 (de) 2002-05-01 2010-03-15 Vertex Pharma Kristallstruktur des aurora-2 proteins und dessen bindungstaschen
EP1506176B1 (de) 2002-05-17 2013-04-24 Pfizer Italia S.r.l. Als kinase-hemmer wirksame aminoindazol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
MXPA04011930A (es) 2002-05-31 2005-03-31 Yamanouchi Pharma Co Ltd Derivados de tetrahidropirano.
US6989451B2 (en) 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
FR2840905B1 (fr) 2002-06-12 2006-07-07 Centre Nat Rech Scient Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
AU2002311176A1 (en) 2002-06-12 2003-12-31 Axia Biosciences, Inc. Chfr protein-catalyzed polyubiquitination of aurora kinase a and aurora kinase b
US7301028B2 (en) 2002-06-14 2007-11-27 Merck & Co., Inc. Mitotic kinesin inhibitors
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
WO2004005283A1 (en) 2002-07-09 2004-01-15 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
AU2003253880A1 (en) 2002-07-15 2004-02-02 Sugen, Inc. Novel kinases
JP2006501191A (ja) 2002-07-17 2006-01-12 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤としてのヘテロ二環式ピラゾール誘導体
AU2003244649A1 (en) 2002-07-25 2004-02-23 Pharmacia Italia Spa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP1530573B1 (de) 2002-07-25 2008-03-19 Pfizer Italia S.r.l. Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren
AU2003244632A1 (en) 2002-07-25 2004-02-25 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP1546117A2 (de) 2002-08-14 2005-06-29 Vertex Pharmaceuticals Incorporated Proteinkinaseinhibitoren und deren verwendungen
JP4799864B2 (ja) 2002-09-23 2011-10-26 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのイミダゾピラジン
AU2003301439A1 (en) 2002-10-16 2004-05-04 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
US6909001B2 (en) 2002-12-12 2005-06-21 Pharmacia Corporation Method of making tricyclic aminocyanopyridine compounds
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
AU2003292435A1 (en) 2002-12-23 2004-07-14 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
WO2004058782A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Therapeutic quinazoline derivatives
PT1847539E (pt) 2002-12-24 2009-10-06 Astrazeneca Ab Derivados de quinazolina
US7407946B2 (en) 2002-12-24 2008-08-05 Astrazeneca Ab Quinazoline compounds
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
DE602004022633D1 (de) 2003-01-30 2009-10-01 Boehringer Ingelheim Pharma 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
WO2004070062A2 (en) 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
EP1592389B1 (de) 2003-02-14 2009-04-22 Laboratoires Serono SA Derivate von piperazine-2-carboxamide
JP2006517949A (ja) 2003-02-17 2006-08-03 ファルマシア・イタリア・ソシエタ・ペル・アツィオーニ キナーゼ阻害剤としての四環系ピラゾール誘導体、前記誘導体の製造方法、および前記誘導体を含む医薬組成物
UA80743C2 (en) 2003-02-26 2007-10-25 Boehringer Ingelheim Pharma Dihydropteridinones, method for the production and use thereof in the form of drugs
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
AR050920A1 (es) 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
CA2518395A1 (en) 2003-03-11 2004-09-23 Pharmacia Italia S.P.A. Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2004221881A1 (en) 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
WO2004087056A2 (en) 2003-03-28 2004-10-14 Scios Inc. BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ
EP1608652A1 (de) 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidinverbindungen und deren verwendung in der medizin
WO2004090106A2 (en) 2003-04-04 2004-10-21 Vertex Pharmaceuticals Incorporated Crystal structures of human pim-1 kinase protein complexes and binding pockets thereof, and uses thereof in drug design
RS20050832A (sr) * 2003-04-09 2007-12-31 Millennium Pharmaceuticals Inc., Beta-karbolini koji su korisni u tretiranju inflamatornih bolesti
PL378813A1 (pl) * 2003-04-11 2006-05-29 Glenmark Pharmaceuticals S.A. Nowe związki heterocykliczne przydatne w leczeniu stanów zapalnych i zaburzeń alergicznych: sposób ich wytwarzania i kompozycje farmaceutyczne zawierające te związki
WO2004094410A1 (en) 2003-04-16 2004-11-04 Astrazeneca Ab Chemical compounds
ATE446752T1 (de) 2003-04-24 2009-11-15 Merck & Co Inc Hemmer der akt aktivität
CN1809351A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
JP4673300B2 (ja) 2003-04-24 2011-04-20 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US20040242559A1 (en) 2003-04-25 2004-12-02 Aventis Pharma S.A. Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors
AU2004236240C1 (en) 2003-05-01 2010-11-04 Bristol-Myers Squibb Company Aryl-substituted pyrazole compounds useful as kinase inhibitors
JP2007500212A (ja) 2003-05-01 2007-01-11 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 新規化合物およびその標的に関する組成物および方法
WO2005000200A2 (en) 2003-05-09 2005-01-06 Sugen, Inc. Novel kinases
US7482354B2 (en) 2003-05-22 2009-01-27 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
US7345046B2 (en) 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
US20060135541A1 (en) 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
TW200505452A (en) 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
WO2004113335A2 (en) 2003-06-20 2004-12-29 Chiron Corporation Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
WO2005009348A2 (en) 2003-06-25 2005-02-03 Ariad Pharmaceuticals, Inc. Substituted purine derivatives
AU2003304266A1 (en) 2003-07-03 2005-01-21 Cambridge University Technical Services Ltd Use of aurora kinase inhibitors for reducing the resistance of cancer cells
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0315657D0 (en) 2003-07-03 2003-08-13 Astex Technology Ltd Pharmaceutical compounds
SI1641775T1 (sl) 2003-07-03 2009-08-31 Euro Celtique Sa 2-piridin alkinski derivati, uporabni za zdravljenje bolečine
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0315966D0 (en) 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP1648900A4 (de) 2003-07-11 2010-02-10 Ariad Pharma Inc Phosphorhaltige makrocyclen
ES2317031T3 (es) 2003-07-16 2009-04-16 Janssen Pharmaceutica Nv Derivados de triazolopirimidina como inhibidores de la glucogeno-sintasa-quinasa 3.
EP1658292B1 (de) 2003-07-16 2007-08-15 Janssen Pharmaceutica N.V. Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
ATE455772T1 (de) 2003-07-21 2010-02-15 Merck Serono Sa Alkinylarylcarbonsäureamide
US20050137220A1 (en) * 2003-07-23 2005-06-23 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
UA84710C2 (ru) 2003-07-24 2008-11-25 Евро-Селтик С.А. Пиперидиновые производные, фармацевтическая композиция, которая их содержит, и способ лечения
US20050026984A1 (en) 2003-07-29 2005-02-03 Aventis Pharma S.A. Substituted thieno [2,3-c] pyrazoles and their use as medicinal products
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
AU2004261482A1 (en) 2003-07-30 2005-02-10 Cyclacel Limited Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
EP1648875A1 (de) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidine als kinaseinhibitoren
US7094791B2 (en) 2003-07-31 2006-08-22 Avalon Pharmaceuticals, Inc. Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
US7279575B2 (en) 2003-08-08 2007-10-09 Pfizer Italia S.R.L. Pyrimidylpyrrole derivatives active as kinase inhibitors
AU2004267094A1 (en) 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated (4 -amino -1,2, 5-oxadiazol-4-yl) -hetxiroaromatic compounds useful as protein kinase inhibitors
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
CA2534317A1 (en) 2003-09-12 2005-03-24 Applied Research Systems Ars Holding N.V. Benzimidazole acetonitriles
AU2004272345A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
DE602004022180D1 (de) 2003-09-16 2009-09-03 Astrazeneca Ab Chinazolinderivate
MXPA06002964A (es) 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
WO2005034840A2 (en) 2003-09-17 2005-04-21 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
CA2539320A1 (en) 2003-09-17 2005-03-31 Icos Corporation Use of chk1 inhibitors to control cell proliferation
ATE433974T1 (de) 2003-09-19 2009-07-15 Gilead Sciences Inc Azachinolinolphosphonatverbindungen als integraseinhibitoren
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
ES2344007T3 (es) 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
MXPA06003746A (es) 2003-10-14 2006-06-14 Pharmacia Corp Compuestos de pirazinona sustituida para el tratamiento de inflamacion.
KR20060123164A (ko) 2003-10-17 2006-12-01 아스트라제네카 아베 암 치료에 사용하기 위한 4-(피라졸-3-일아미노)피리미딘유도체
WO2005037797A1 (en) 2003-10-21 2005-04-28 Pharmacia Corporation Substituted pyrazole urea compounds for the treatment of inflammation
JP5164380B2 (ja) 2003-10-21 2013-03-21 サイクラセル リミテッド ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用
BRPI0415678A (pt) 2003-10-23 2006-12-19 Pharmacia Corp compostos de pirimidina para o tratamento de inflamação
WO2005044270A1 (en) 2003-11-04 2005-05-19 4Sc Ag Oxadiazolopyrazine derivatives as pharmaceutically active compounds
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20050107386A1 (en) 2003-11-19 2005-05-19 Rama Krishna Narla Methods of treating diseases and disorders by targeting multiple kinases
US7473783B2 (en) 2003-12-17 2009-01-06 Sgx Pharmaceuticals, Inc. Bicyclic pyrazolo protein kinase modulators
FR2864084B1 (fr) 2003-12-17 2006-02-10 Aventis Pharma Sa Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
WO2005071419A2 (en) 2004-01-16 2005-08-04 Ipsogen Protein expression profiling and breast cancer prognosis
JP2007518822A (ja) 2004-01-23 2007-07-12 カイロン コーポレイション 抗癌剤としてのテトラヒドロカルボリン化合物
TW200526204A (en) 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
FR2865934B1 (fr) 2004-02-05 2006-05-05 Sanofi Synthelabo Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
TW200536536A (en) 2004-02-25 2005-11-16 Schering Corp Pyrazolotriazines as kinase inhibitors
US20050288347A1 (en) 2004-03-26 2005-12-29 Hodge Carl N Certain triazole-based compounds, compositions, and uses thereof
WO2005094830A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
NZ584499A (en) 2004-03-30 2011-08-26 Vertex Pharma Azaindoles Useful as Inhibitors of Jak and Other Protein Kinases
FR2868421B1 (fr) 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
EP1763524A1 (de) 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indolderivate und deren verwendung als kinaseinhibitoren
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
WO2005105777A1 (en) 2004-05-05 2005-11-10 Pharmacia & Upjohn Company Llc Substituted thiophene amide compounds for the treatment of inflammation
MXPA06012613A (es) 2004-05-07 2007-01-31 Amgen Inc Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
RS50568B8 (sr) 2004-05-14 2019-08-30 Millennium Pharm Inc Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze
JP4812763B2 (ja) 2004-05-18 2011-11-09 ライジェル ファーマシューティカルズ， インコーポレイテッド シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
JPWO2005113550A1 (ja) 2004-05-20 2008-03-27 三菱ウェルファーマ株式会社 アミノピリミジン誘導体及びその医薬としての用途
CA2564215A1 (en) 2004-05-21 2005-12-01 Chiron Corporation Substituted quinoline derivatives as mitotic kinesin inhibitors
WO2005117943A2 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Biomarkers for monitoring inhibition of impdh pathway
JP2008501628A (ja) 2004-06-02 2008-01-24 武田薬品工業株式会社 インドール誘導体およびがんの治療用途
US7452887B2 (en) 2004-06-04 2008-11-18 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
MXPA06014021A (es) 2004-06-04 2007-02-08 Pfizer Prod Inc Procedimiento para tratar crecimiento celular anormal.
WO2005123672A2 (en) 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
CA2568756A1 (en) 2004-06-15 2005-12-29 Astrazeneca Ab Substituted quinazolones as anti-cancer agents
JP4836280B2 (ja) 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
WO2006002367A1 (en) 2004-06-23 2006-01-05 Irm Llc Compounds and compositions as protein kinase inhibitors
US7879853B2 (en) 2004-06-28 2011-02-01 Bayer Schering Pharma Ag 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
TW200616974A (en) 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
WO2006007496A2 (en) 2004-07-01 2006-01-19 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2571824A1 (en) 2004-07-01 2006-01-19 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2006003440A1 (en) 2004-07-05 2006-01-12 Astex Therapeutics Limited 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors
CA2571937A1 (en) 2004-07-08 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of pkc-theta
EP1768956A1 (de) 2004-07-12 2007-04-04 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amidderivate als histondeacetylase-hemmer
AU2005261487A1 (en) 2004-07-12 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide derivatives as inhibitors of histone deacetylase
DE102004034623A1 (de) 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE602005024274D1 (de) 2004-07-16 2010-12-02 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
US20080261821A1 (en) 2004-07-21 2008-10-23 The Regents Of Te University Of California Mechanism-Based Crosslinkers
JP2008506761A (ja) 2004-07-22 2008-03-06 アステックス、セラピューティックス、リミテッド プロテインキナーゼ阻害剤としてのチアゾールおよびイソチアゾール誘導体
EP1773830A1 (de) 2004-07-22 2007-04-18 AstraZeneca AB Für die behandlung und prävention von krebs geeignete kondensierte pyrimidone
US7361763B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US20090239214A1 (en) 2004-07-30 2009-09-24 Hongyue Dai Prognosis of breast cancer patients
EP1797054A2 (de) 2004-08-02 2007-06-20 OSI Pharmaceuticals, Inc. Arylaminosubstituierte pyrrolopyrimidine als multikinaseinhibierende verbindungen
WO2006017549A2 (en) 2004-08-03 2006-02-16 Vertex Pharmaceuticals Incoporated Cell-based kinase assay
WO2006023083A1 (en) 2004-08-12 2006-03-02 Merck & Co., Inc. Mitotic kinesin inhibitors
ES2401138T3 (es) 2004-08-13 2013-04-17 Genentech, Inc. Inhibidores basados en tiazol de enzimas que usan ATP
WO2006023440A2 (en) 2004-08-18 2006-03-02 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
CA2576057A1 (en) 2004-08-18 2006-03-23 Merck & Co., Inc. Mitotic kinesin inhibitors
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
EP1784175A4 (de) 2004-08-23 2009-07-22 Merck & Co Inc Inhibitoren von akt-aktivität
CA2575804A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
JP2008510771A (ja) 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用
EP1786265A4 (de) 2004-08-30 2009-08-19 Smithkline Beecham Corp Neue zusammensetzungen und behandlungsverfahren
CN101010303A (zh) 2004-09-01 2007-08-01 阿斯利康(瑞典)有限公司 喹唑啉酮衍生物和它们作为b－raf抑制剂的用途
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
AR050926A1 (es) 2004-09-03 2006-12-06 Astrazeneca Ab Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac)
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
EP1796467A4 (de) 2004-09-24 2009-07-01 Janssen Pharmaceutica Nv Imidazo{4,5-b}pyrazinon-hemmer von proteinkinasen
US20060069101A1 (en) 2004-09-27 2006-03-30 Kim Kyoung S Prodrugs of protein tyrosine kinase inhibitors
US20060079494A1 (en) 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors
CA2582235A1 (en) 2004-10-04 2006-04-20 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
FR2876377B1 (fr) 2004-10-11 2007-03-16 Univ Claude Bernard Lyon Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
AU2005293336B2 (en) 2004-10-12 2009-05-28 Astrazeneca Ab Quinazoline derivatives
MX2007004480A (es) 2004-10-15 2007-05-08 Astrazeneca Ab Quinoxalinas como inhibidores b raf.
EP1828165B1 (de) 2004-10-29 2013-03-20 Msd K.K. Neue aminopyridinderivate mit einer selektivaurora-a-hemmenden wirkung
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
EP1814883A1 (de) 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Bicyclische rho-kinase-hemmer
GB0427917D0 (en) 2004-12-21 2005-01-26 Astrazeneca Ab Chemical compounds
ITPI20040099A1 (it) 2004-12-24 2005-03-24 Maurizio Pacini Sistema di realizzazione di tappeto erboso mediante micro-plantule preradicate
EP1836199A1 (de) 2004-12-30 2007-09-26 Astex Therapeutics Limited Die aktivität von cdk, gsk und aurora-kinasen modullierende thiazol- und isothiazolderivate
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
EP2395000A1 (de) 2004-12-30 2011-12-14 Astex Therapeutics Limited Benzimidazolverbindungen, die die Aktivität von CDK, GSK und Aurora-Kinasen modulieren
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
FR2882751B1 (fr) 2005-03-04 2007-09-14 Aventis Pharma Sa Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, procede de preparation, compositions les contenant et utilisation
GB0504475D0 (en) 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0504474D0 (en) 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
FR2884821B1 (fr) 2005-04-26 2007-07-06 Aventis Pharma Sa Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0509224D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
WO2006130673A1 (en) 2005-05-31 2006-12-07 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
EP1896472A1 (de) 2005-06-09 2008-03-12 Boehringer Ingelheim International GmbH Alpha-carboline als cdk-1 inhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010500961A (ja) * 2006-08-02 2010-01-14 武田薬品工業株式会社 α−カルボリン誘導体およびその製造方法
GEP20135728B (en) * 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
EP2223925A1 (de) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase-Inhibitoren
CA2666130A1 (en) 2006-10-09 2008-04-17 Takeda San Diego, Inc. Kinase inhibitors
EP2079696A2 (de) 2006-10-09 2009-07-22 Takeda San Diego, Inc. Kinase-inhibitoren
US20090312288A1 (en) * 2008-04-16 2009-12-17 Takeda Pharmaceutical Company Limited Kinase inhibitors

Also Published As

Publication number Publication date
KR20080051153A (ko) 2008-06-10
US8318939B2 (en) 2012-11-27
EP2133349B1 (de) 2011-01-12
CR9886A (es) 2008-08-01
ZA200802820B (en) 2010-02-24
AU2006302135A1 (en) 2007-04-19
CN101356172B (zh) 2012-06-13
ES2358006T3 (es) 2011-05-04
US20070117816A1 (en) 2007-05-24
PT2133349E (pt) 2011-03-17
CN101356172A (zh) 2009-01-28
NO20081564L (no) 2008-07-02
MA29796B1 (fr) 2008-09-01
DE602006019651D1 (de) 2011-02-24
GEP20125368B (en) 2012-01-10
CY1111346T1 (el) 2015-08-05
US20100190816A1 (en) 2010-07-29
JP2009511503A (ja) 2009-03-19
JP5150878B2 (ja) 2013-02-27
MY146989A (en) 2012-10-15
EP2133349A1 (de) 2009-12-16
EP1931669A1 (de) 2008-06-18
AU2006302135B2 (en) 2012-05-17
EA015902B1 (ru) 2011-12-30
RS51897B (sr) 2012-02-29
DK2133349T3 (da) 2011-03-28
HRP20110220T1 (hr) 2011-04-30
IL190306A0 (en) 2009-09-22
WO2007044779A1 (en) 2007-04-19
HK1138842A1 (en) 2010-09-03
EA200800725A1 (ru) 2009-02-27
SI2133349T1 (sl) 2011-05-31
US8119655B2 (en) 2012-02-21
CA2624610A1 (en) 2007-04-19
PL2133349T3 (pl) 2011-08-31
BRPI0616950A2 (pt) 2009-11-24
AU2006302135A2 (en) 2009-12-17
NZ566866A (en) 2011-12-22

Similar Documents

Publication Publication Date Title
NO20081564L (no) Kinaseinhibitorer
FIC20210022I1 (fi) tukatinibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan tai solvaatin muodossa
PL1682138T6 (pl) Heterocykliczne inhibitory MEK
TW200519084A (en) Cyclic amine bace-1 inhibitors having a benzamide substituent
CY1116882T1 (el) Ιμιδαζολοθειαδιαζολια προς χρηση ως αναστολεις πρωτεϊνικων κινασων
WO2009060197A8 (en) Imidazopyridazines for use as protein kinase inhibitors
EP2205088A4 (de) Auf naphthalin basierende hemmer von anti-apoptotischen proteinen
MX2007009372A (es) Nuevos compuestos ii derivados de 2-piridina como inhibidores de elastasa neutrofila.
ATE542800T1 (de) Kinasehemmer und ihre anwendungsverfahren
EP2145878A3 (de) Aurora Kinase-inhibitoren
EA200801199A1 (ru) Ингибиторы киназы
MY143516A (en) Kinase inhibitors
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
TW200635592A (en) Pyridyl-substituted spiro-hydantoin compounds and use thereof
MY147487A (en) Aryl carboxylic acid syslohexyl amide derivatives
TW200616642A (en) CRP lowering agent
WO2010009985A3 (en) Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2133349

Country of ref document: EP